Press Release
NPS Reports Three Teduglutide Abstracts Accepted for Presentation at Digestive Disease Week Conference
| Oral Presentations: | |||||
| Abstract 897: “Teduglutide, a Novel GLP-2 Analogue, Decreases Fecal Wet Weight, Sodium and Potassium Excretion in Short Bowel Syndrome (SBS) Patients Dependent on Parenteral Nutrition (PN)” by B. Jeppesen et al. will be presented on June 2, 2009 from 4:00 – 4:15 pm, Central Daylight Time. | |||||
| Abstract 898: “Citrulline: a Potential Predictor of Reductions in Parenteral Nutrition Achieved in Chronic Parenteral Nutrition Dependant Patients with Short Bowel Syndrome (SBS) Treated with Teduglutide” by R. Gilroy et al. will be presented on June 2, 2009 from 4:15 – 4:30 pm, Central Daylight Time. | |||||
| Poster Session: | |||||
| Abstract T1281: “The Influence of Teduglutide, a Novel GLP-2 Analogue, on Energy Absorption in Short Bowel Syndrome (SBS) Patients Dependent on Parenteral Nutrition (PN)” by B. Jeppesen et al. will be presented on June 2, 2009 from 8:00 am – 5:00 pm, Central Daylight Time. | |||||
The DDW program and abstracts are available online at the DDW website
and can be accessed at http://www.ddw.org
by clicking on the program page and accepted abstracts link, creating a
MyDDW account, and searching for teduglutide or the abstract author.
Accepted abstracts will be published in a supplement to either the
About Short Bowel Syndrome (SBS)
SBS is a highly disabling condition that impairs quality of life and can
lead to serious life-threatening complications. SBS typically arises
after extensive resection of the bowel. There are an estimated 10,000 to
15,000 SBS patients in
About GATTEX™ (teduglutide)
GATTEX (teduglutide) is a proprietary analog of human glucagon-like peptide 2 that stimulates the repair and regeneration of cells lining the intestine. GATTEX is in Phase 3 clinical development to reduce dependence on parenteral nutrition (PN) in patients with short bowel syndrome (SBS). NPS has reported positive findings from recently completed studies in which GATTEX demonstrated a favorable safety profile and significant reductions in mean PN volume from pretreatment baseline were observed. NPS is also advancing preclinical studies to evaluate teduglutide in additional intestinal failure related conditions.
Teduglutide has received orphan drug designation for the treatment of
SBS from the
About DDW
DDW is the largest international gathering of physicians, researchers
and academics in the fields of gastroenterology, hepatology, endoscopy
and gastrointestinal surgery. Jointly sponsored by the
About
“NPS” and “NPS Pharmaceuticals” are the company’s registered trademarks. Preotact® is the company’s registered trademark in the U.S. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements are based on the company's current expectations and
beliefs and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. Risks associated to the company’s
business include, but are not limited to, the risks associated with any
failure by the company to successfully complete its preclinical and
clinical studies within the projected time frames or not at all, the
risk of not gaining marketing approvals for GATTEX and NPSP558, the
risks associated with the company’s strategy, the risks associated with
the company’s auction-rate securities, as well as other risk factors
described in the company’s periodic filings with the
Source:
Investors:
NPS Pharmaceuticals, Inc.
Susan M. Mesco,
908-450-5516
smesco@npsp.com
or
Media:
WeissComm
Partners
Edie DeVine, 209-814-9564
edevine@wcpglobal.com
The reports filed by NPS with the Securities and Exchange Commission and the news releases issued by NPS and posted on this website are current only as of the dates on which they were filed or issued by NPS. Therefore, the contents of these reports and releases can become outdated. We make no commitment, and disclaim any duty, to update these reports and releases. We do not warrant the accuracy or completeness of these materials or the reliability of any advice, opinion, statement or other information displayed or distributed through the website. Readers acknowledge that any reliance on these reports, releases, advice, opinions, statements, or information are at the reader’s sole risk.